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tissue (most often the face, hands, feet), but also very dangerous 
edemas of the mucosa of the digestive system, throat and larynx 
may appear [2]. Attacks occur spontaneously or are induced for 
instance by stress, mechanical trauma or infection. In patients 
with HAE-C1INH, it is absolutely necessary to avoid drugs that 
may intensify bradykinin edema – angiotensin-converting enzyme 
inhibitors (ACEI) and estrogens [1, 2]. Angioedema usually develops 
slowly, but if left untreated or treated improperly, it may result in 
death. Laryngeal attacks are particularly dangerous for patients, 
that is why the correct diagnosis and appropriate treatment are so 
important. Undiagnosed laryngeal attacks in the course of HAE-
C1INH are characterized by high mortality reaching 50% [3].
In the diagnosis of hereditary angioedema, plasma levels of C4, 
C1-inhibitor antigen and C1-inhibitor function are measured. Levels 
of all these parameters are reduced in HAE-1, whereas in HAE-
2 C1INH function is reduced, but not C1INH antigen level (see 
– supplementary materials) [1]. In the treatment of severe HAE-C1INH 
attacks in Poland, the supplementation of the missing protein with 
intravenous C1-inhibitor preparations is used: plasma-derived 
(Berinert – 20 U/kg, usually 1 amp. a 1500 U) or recombinant human 
(Ruconest – 50 U/kg, usually 2 amp., a total of 4200 U), as well 
as icatibant, a subcutaneous inhibitor of bradykinin B2 receptors 
LIST OF ABBREVIATIONS
ACEI – angiotensin-converting enzyme inhibitors 
C1INH – C1-inhibitor 
HAE – Hereditary angioedema 
HAE-1 – Hereditary angioedema type 1 
HAE-2 – Hereditary angioedema type 2 
HAE-C1INH – Hereditary angioedema caused by C1-inhibitor 
deficiency
INTRODUCTION
Hereditary angioedema caused by C1-inhibitor deficiency 
(HAE-C1INH) is a rare genetic disease with autosomal dominant 
inheritance. The cause of the disease is C1-inhibitor deficiency 
(C1INH): quantitative (low level of C1INH antigen) in HAE type 
1 (HAE-1) or qualitative (low functional C1INH level) in HAE 
type 2 (HAE-2) [1]. The deficiency in the C1-inhibitor leads to 
disinhibition of cleavage of bradykinin from high-molecular-
weight kininogen by kallikrein and, as a result, to overproduction of 
bradykinin responsible for vasodilatation and excessive permeability 
of capillaries. In consequence,  angioedema attacks of subcutaneous 
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RESULTS
The characteristic clinical determinants of the two groups 
of patients, with and without laryngeal attacks in the course 
of HAE-C1INH, observed during the last six months were 
compared in Tab. I. The number of laryngeal attacks was: 1–3 
attacks in 9 patients, 4–6 in 8 patients, ≥7 attacks in 2 patients. 
In one individual the number of laryngeal attacks in the last 
6 months reach up to 18. Intubation was performed in 
2 respondents, and further 4 patients managed to avoid intubation 
due to regression of angioedema after the administration of 
C1-inhibitor preparations. The severity score of the disease, which 
takes into account location, duration and treatment of attacks, 
was assessed as “severe” in all patients with laryngeal edema [2, 7]. 
The factor that most often induced angioedema attacks in both 
groups was mental stress, but in the group with laryngeal episodes 
it was significantly more frequent. Similarly, facial edema and 
female sex occurred significantly more frequently in the group 
with laryngeal attacks.
Data on the treatment of HAE-C1INH attacks are presented in 
Tab. II. Patients in both groups most often used plasma-derived 
C1-esterase inhibitor and icatibant. All patients in the group with 
a history of laryngeal angioedema had a rescue medication at home, 
and 79% of them administered the medicine themselves or it was 
given to them by a family member after an appropriate training. 
A few subjects used tranexamic acid or danazol for the long-term 
prophylaxis of HAE-C1INH attacks.
(Firazyr – 30 mg/kg) [2, 4]. When they are lacking, fresh frozen 
plasma (2–3 units) might be administered. An effectively treated 
angioedema attack disappears within a few hours. It is important, 
especially in patients with laryngeal attacks, to administer the 
drug as soon as possible to stop the edema at an early stage. Rapid 
administration of the drug is possible thanks to appropriate training 
of patients and their families in the technique of self-administration 
of life-threatening emergency treatments. All the above-mentioned 
drugs are approved for self-administration at home. Laryngeal 
angioedema in the course of HAE-C1INH is resistant to treatment 
with glucocorticosteroids and antihistamines, therefore these drugs 
are not recommended for those patients. All patients with laryngeal 
attacks, also after administration of appropriate treatment, should 
be observed in hospital setting [1, 2, 5].
During a laryngeal attack, apart from ensuring proper treatment, 
a patient should also be appropriately positioned – with the head 
slightly backwards to maintain a patent airway. Any manipulation 
that causes mechanical irritation of the larynx mucosa may increase 
the swelling, therefore any intubation of a patient should be per-
formed by an experienced physician. In the case of ineffective con-
servative treatment, tracheotomy or coniotomy is performed [5, 6].
MATERIALS AND METHODS
Patients: The study included 55 adults (20 men, 35 women) aged 
18–76 years (mean age – 40 years, SD – 13.5) diagnosed with 
hereditary angioedema due to C1-INH deficiency, consecutively 
reporting to the Center of Clinical Allergology University Hospital 
in Krakow for regular visits and having angioedema attacks in the 
last 6 months preceding the study. Children (<18 years old) and 
asymptomatic patients were excluded from the study. A group of 
19 patients reporting laryngeal attacks within the last six months 
was separated from the study group. Prior the study, patients signed 
informed consent of participation. The study was carried out in 
accordance with the requirements of the Helsinki Declaration and 
obtained the permission of the local bioethics committee. 
Methods: A structured clinical questionnaire was used for a detailed 
clinical evaluation of patients, including questions about the course 
and treatment of HAE-C1INH in the last 6 months and focusing 
particularly on laryngeal swelling attacks. The study group was 
divided into two subgroups: patients with and without laryngeal 
attacks. In order to find some clinical features characteristic for 
patients with laryngeal angioedema attacks, both groups were 
compared in respect to: frequency and location of all HAE-C1INH 
attacks, trigger factors, prodromal and accompanying symptoms, 
treatment and access to self-administered rescue medication. The 
severity of HAE-C1INH was assessed according to the scale (“severe”, 
“moderate”, “mild”, “minimal”) proposed by Agostoni et al. [7].
Statistical analysis: A two-tailed Chi-square test with Yates’ 
correction and Fisher’s exact test were applied to compare the 
groups. The mean values between groups were compared with 
Mann-Whitney test. P-value < 0.05 was considered statistically 
significant. Statistical analyses were performed using GraphPad 
Software (La Jolla, CA, USA).
Tab. I.  Comparison of the group of patients with and without laryngeal attacks in the 
course of HAE-C1INH. 
PATIENTS wITH 
LARyNGEAL ATTACKS 
NO (%)
PATIENTS wITHOUT 
LARyNGEAL 
ATTACKS NO (%)
P VALUE
Number of subjects 19 (34.5) 36 (65.5) ND
Mean age 39.8 lat (SD 14.8) 40.1 lat (SD 13) ns
Gender (M/F) 2/17 (10.5/89.5) 18/18 (50/50) 0.009
Type of HAE-C1INH 
(HAE-1/HAE-2)
18/1 (94.7/5.3) 30/6 (83.3/16.7) ns
Location of attacks ns
abdominal 18 (94.7) 30 (83.3) ns
peripheral 19 (100) 31 (86.1) 0.013
facial 12 (63.2) 9 (25) ns
another (chest, neck, 
genitals)
12 (63.2) 18 (50) 0.008
Severe disease activity 19 (100) 23 (64) ns
Age of onset of attacks 8.5 lat (SD 6) 11.6 lat (SD 11.6) 0.015
Triggers 17 (89.5) 20 (55.6) ns
mental stress 15 (79) 18 (50) ns
physical trauma 13 (36.1) 14 (38.9) ns
infection 8 (47.1) 9 (50) ns
menstruation ns
HAE-C1INH in family 15 (79)
Death related to HAE-
C1INH in family
3 (15.8) 13 (36.1)
SD – standard deviation; ns – not significant; NA – not applicable 
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position of the larynx [6] facilitates faster spread of throat swelling 
to further parts of the respiratory tract.
A very positive fact is that all patients with laryngeal attacks had 
a rescue medication at home and nearly 80% of them were able to 
administer it themselves or with the help of a family member. This 
indicates high awareness of the risks associated with the disease. 
Patients with laryngeal attacks most often used plasma-derived 
C1-INH (pd-C1INH) and icatibant. Pd-C1INH is the longest used 
emergency treatment in Poland and patients with dangerous symp-
toms readily reach for it. A summary analysis of various therapeu-
tic options in the treatment of laryngeal attacks by Bork et al. [8] 
indicates that intravenous pd-C1INH administered at the full rec-
ommended dose could be regarded as the treatment producing the 
most reliable response. In turn, an apparent advantage of icatibant 
is the subcutaneous way of its administration, which shortens the 
time from symptom onset to the start of the treatment, and in con-
sequence reduces the duration and severity of an angioedema attack 
[9]. The effectiveness of icatibant in laryngeal attacks was confirmed 
by observations carried out in everyday practice [10]. In the cases 
of HAE-C1INH larynx edemas, the alarm symptoms that require 
immediate treatment are: feeling of having a lump and/or feeling of 
tightness in the throat, swallowing difficulties [11].
HAE-C1INH patients with laryngeal attacks require particular attention. 
Proper training in dealing with those patients, providing emergency 
treatment and quick access to emergency care units are necessary 
to ensure the safety of the patients with this type of HAE-C1INH 
attacks. The group of patients with laryngeal attacks remaining 
under the care of our center exemplify and confirm these statements. 
So far, all our patients have been successfully treated during laryngeal 
attacks thanks to a properly conducted therapy and appropriate 
training. In case of recurrent, refractory to glucocorticosteroids and 
antihistamines laryngeal swellings, especially with an accompanying 
positive family history, hereditary angioedema due to C1-inhibitor 
deficiency should always be taken into account in the differential 
diagnosis and management (see additional materials) [12, 13, 14].
DISCUSSION
Among the patients with hereditary angioedema caused by 
C1-inhibitor deficiency, attacks of laryngeal edema are not 
uncommon (attacks within the last 6 months in 34.5% of the 
study group). Around 50% of HAE-C1INH patients experience 
angioedema of the larynx during their lifetime [5]. In 100% of 
our patients with laryngeal attacks, the severity of the disease 
according to Agostoni scale [7] was assessed as severe. This means 
that all patients have had a high number of attacks not only of the 
larynx, but also in other locations over the past six months, which 
indicates that the overall course of the disease in patients with 
laryngeal swelling episodes is more severe. Our observations show 
that facial attacks are more common in patients with laryngeal 
angioedema, which is also described in the literature [5]. The 
significant predominance of women in the group of patients with 
laryngeal attacks (89.5%) is noteworthy. This may result from 
estrogen activity, which deteriorates HAE-C1INH and from the 
anatomical conditions of the larynx in women, namely the higher 
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Tab. II.  Treatment of patients with laryngeal attacks in the course of HAE-C1INH and 
a group without laryngeal attacks.
PATIENTS wITH 
LARyNGEAL 
ATTACKS NO (%)
PATIENTS wITHOUT 
LARyNGEAL 
ATTACKS NO (%)
P VALUE
Emergency medication 
(in the last 6 months)
pdC1-INH 17 (89.5) 21 (58.3) 0.03
icatybant 8 (42.1) 16 (44.4) ns
rhC1-INH 1 (5.3) 3 (8.3) ns
Long-term prophylaxis
tranexamic acid 2 (10.6) 1 (2.8) ns
danazol 2 (10.6) 1 (2.8) ns
Rescue medication at home 19 (100) 33 (91.7) ns
Self- administration or Adminis-
tration by a family member
15 (79) 24 (66.7) ns
pd-C1INH – plasma-derived C1INH; rh-C1INH – human recombinant C1INH; ns – not significant
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KEY POINTS: 
 
▪ Hereditary angioedema (HAE) is rare disease characterized by recurrent episodes of swelling in the 
absence of concomitant urticaria or use of medication known to induce angioedema; 
 
▪ Angioedema attacks involve the extremities, intestinal tract, upper airways or genitals. Laryngeal 
attacks are potentially life-threatening. Attacks do not respond to typical anti-allergic treatment; 
 
▪ The most common HAE type is hereditary angioedema due to C1-inhibitor (HAE-C1INH) deficiency 
(estimated prevalence 1:50 000 in general population). Deficiency in C1INH lead to increased production 
of bradykinin, mediates capillary permeability, and in consequence angioedema; 
 
▪ The other HAE types are much less prevalent and involve types either with known genetic background 
(HAE-F12, HAE-PLG, HAE-ANG) or HAE-UNK (a family history of angioedema without a genetic variant 
associated with the disease). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laboratory findings in HAE: 
 
Evaluation of angioedema in emergency conditions 
life-threatening symptoms in upper airways 
• dysphonia, 
• stridor, 
• feeling of having a lump,  
• feeling of tightness in the throat, 
• swallowing difficulties, 
• lingual edema. 
↓ - low, N - normal, *positive family history of angioedema situation 
 
Therapies for HAE-C1INH acute attacks* 
Treatment Mechanism of action Dose and route of administration 
icatibant antagonist of bradykinin 2 receptors 30 mg subcutaneous injection, dose-
adjusted for adolescents <65 kg and children 
>2 years 
pd-C1INH replaces C1INH 20 U/kg intravenous 
rh-C1INH replaces C1INH 4200 U (≥84 kg), 50 U/kg (<84 kg), 
intravenous 
FFP replaces C1INH 2U (< 90 kg), 3U (>90 kg) 
 
pd-C1INH, plasma-derived C1INH; rh-C1INH, human recombinant C1INH; FFP, fresh frozen plasma *approved and reimbursed in Poland 
 
 
REFERENCE CENTER in POLAND: Center of Clinical and Environmental Allergology, University Hospital 
in Krakow, Botaniczna 3, 31-503 Krakow, Poland; phone: 12 424 86 50 
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 C4 C1INH 
level 
C1INH 
function 
Gene mutation 
HAE-1 ↓ ↓ ↓ SERPING-1 
HAE-2 ↓ N ↓ SERPING-1 
HAE-F12 N factor 12 
HAE-PLG N plasminogen 
angiopoietin-1 
unidentified* 
HAE-ANG N 
HAE-1-UNK N 
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